N-Palmitoylethanolamide-Oxazoline Protects against Middle Cerebral Artery Occlusion Injury in Diabetic Rats by Regulating the SIRT1 Pathway

Fusco R, Scuto M, Cordaro M, D'Amico R, Gugliandolo E, Siracusa R, Peritore AF, Crupi R, Impellizzeri D, Cuzzocrea S, Di Paola R. Int J Mol Sci. 2019 Sep 29;20(19):4845.

Laboratory studyOther animalsWith PEA-OXA (2-pentadecyl-2-oxazoline, a PEA analogue, tested alone)

This study tested palmitoylethanolamide together with PEA-OXA (2-pentadecyl-2-oxazoline, a PEA analogue, tested alone). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design

Laboratory study

Subjects

Diabetic rats with focal cerebral ischemia induced by transient middle cerebral artery occlusion (MCAo)

Dose used in the study

PEA-OXA; dose and route not stated in the abstract

Duration

Not stated in the abstract

What was measured

Neurological severity score and infarct volume; tissue histology, apoptosis markers (caspases, Bax, Bcl-2, TUNEL); mast cell degranulation; NF-kappa-B pathway, cytokines and neurotrophic factors.

What the authors reported

PEA-OXA treatment improved tissue histology, reducing lesion size and apoptosis, and reduced mast cell degranulation and NF-kappa-B pathway, cytokine and neurotrophic factor changes caused by MCAo.

Limits of this study

An animal model of diabetic stroke; it cannot show effect in people. Salvatore Cuzzocrea is a co-inventor on PEA-related patents held with Epitech Group, described as unrelated to this study.

Source

PubMed 31569558 · doi:10.3390/ijms20194845

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.